All News
Filter News
Found 2,228 articles
-
Moderna announced mixed interim results Thursday from a Phase III trial of mRNA seasonal flu vaccine candidate, mRNA-1010.
-
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
2/17/2023
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age.
-
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs
2/16/2023
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines access to Logica™
-
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
2/16/2023
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010, an mRNA-based seasonal influenza vaccine candidate, in adults.
-
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
2/15/2023
Sesen Bio, Inc., announced that BML Investment Partners, L.P., one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc.
-
AstraZeneca announced it is making significant cuts from its pipeline in an attempt to realign its priorities and recover from waning COVID-19 drug sales.
-
Amid growing demands for generic versions of Vertex’s Trikafta, the company provided an update on the late-stage clinical development of its next-in-class triple combination for cystic fibrosis.
-
Catalent, Inc. Reports Second Quarter Fiscal 2023 Results
2/7/2023
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.
-
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
2/7/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2022 and provided full year 2023 financial guidance.
-
Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board
2/7/2023
Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company's Scientific Advisory Board (SAB).
-
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
2/3/2023
Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.
-
Medidata Experts Present New Insights on Risk-Based Quality Management, Decentralized Clinical Trials, and Real World Data at SCOPE Summit
2/3/2023
Medidata, a Dassault Systèmes company, will be leading multiple sessions at the upcoming Summit for Clinical Ops Executives (SCOPE) on trial diversity, risk based quality management (RBQM), decentralized clinical trials (DCT), real world data, sensors and wearables, and randomization and trial supply management (RTSM).
-
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2/2/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
-
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
2/2/2023
Sesen Bio, Inc. filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.
-
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
2/2/2023
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update.
-
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
2/1/2023
Ratio Therapeutics Inc. announces the close of its Series A financing extension today, bringing the total raised to date to over $40 million.
-
The FDA granted Moderna's RSV vaccine candidate Breakthrough Therapy Designation Monday.
-
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
1/30/2023
Moderna, Inc. today announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.
-
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
1/26/2023
CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.
-
Myosana Therapeutics Raises $5 Million in Seed Funding
1/25/2023
Myosana Therapeutics, Inc. today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.